Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.45 |
| ▸ | ESR1 | P03372 | 10/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.43 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.43 |
| ▸ | WIZ | O95785 | 1/20 | 0.42 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.42 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30942254 | 1.00 | CRBN (0.45) | CRBNESR1DDB1IKZF2WIZ | |
| SCHEMBL27423586 | 0.94 | CRBN (0.47) | CRBNESR1DDB1IKZF2WIZ | |
| SCHEMBL30961227 | 0.94 | CRBN (0.47) | CRBNESR1DDB1IKZF2WIZ | |
| SCHEMBL27301645 | 0.91 | CRBN (0.45) | CRBNESR1DDB1IKZF2WIZ | |
| SCHEMBL27423928 | 0.91 | CRBN (0.45) | CRBNESR1DDB1IKZF2WIZ | |
| SCHEMBL30942453 | 0.91 | CRBN (0.45) | CRBNESR1DDB1IKZF2WIZ | |
| SCHEMBL24571664 | 0.90 | CRBN (0.52) | CRBNESR1DDB1IKZF2WIZ | |
| SCHEMBL27423998 | 0.89 | CRBN (0.52) | CRBNESR1DDB1IKZF2WIZ | |
| SCHEMBL30942213 | 0.89 | CRBN (0.52) | CRBNESR1DDB1IKZF2WIZ | |
| SCHEMBL30942438 | 0.87 | CRBN (0.47) | CRBNESR1DDB1IKZF2WIZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | KRAS, VHL, HRAS | CRBN 276/4885ESR1 1673/4885DDB1 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.